High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: study protocol for TBTC Study 31/ACTG A5349 phase 3 clinical trial

INTRODUCTION: Phase 2 clinical trials of tuberculosis treatment have shown that once-daily regimens in which rifampin is replaced by high dose rifapentine have potent antimicrobial activity that may be sufficient to shorten overall treatment duration. Herein we describe the design of an ongoing phas...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Contemp Clin Trials
Huvudupphovsmän: Dorman, Susan E., Nahid, Payam, Kurbatova, Ekaterina V., Goldberg, Stefan V., Bozeman, Lorna, Burman, William J., Chang, Kwok-Chiu, Chen, Michael, Cotton, Mark, Dooley, Kelly E., Engle, Melissa, Feng, Pei-Jean, Fletcher, Courtney V., Ha, Phan, Heilig, Charles M., Johnson, John L., Lessem, Erica, Metchock, Beverly, Miro, Jose M., Nhung, Nguyen Viet, Pettit, April C., Phillips, Patrick P.J., Podany, Anthony T., Purfield, Anne E., Robergeau, Kathleen, Samaneka, Wadzanai, Scott, Nigel A., Sizemore, Erin, Vernon, Andrew, Weiner, Marc, Swindells, Susan, Chaisson, Richard E.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2020
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7307310/
https://ncbi.nlm.nih.gov/pubmed/31981713
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cct.2020.105938
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk